Based on this methylation signature, patients with PC bone metastases could be stratified into one of two patient groups; MCA positive patients being likely to respond to ADT and possibly also other AR targeting therapies or MCA negative patients being less responsive to AR targeting therapies, but possibly suitable for treatment with AR inhibitors in combination with epigenetic modulators (currently in clinical trials, https://clinicaltrials.gov). This evidence concerns the gene AR and pachyonychia congenita.